No groundbreaking research in those skin conditions that you mention (you may want to take a look at BOT for that) and therefore none of the huge expenses associated with "groundbreaking" research; what's making BDA stands apart is actually their capacity for generating revenues immediately and having a nicely set plan to growth.
Quarterly shall be out soon and BDA's value may appear clearer then.
Ann: Update on Fast Track of Phase I Clinical Trials, page-8
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| BOD (ASX) Chart |
Day chart unavailable